Overview
Geftinat contains Gefitinib 250 mg, a targeted anticancer drug used in the treatment of non-small cell lung cancer (NSCLC). It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), specifically targeting the epidermal growth factor receptor (EGFR) pathway. It is indicated for patients whose tumors show EGFR mutations, helping to slow or stop the growth of cancer cells.





